Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [31] The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program
    Pivot, X.
    Poole, C.
    Martin, M.
    Gligorov, J.
    Barrios, C. H.
    Vrdoljak, E.
    Zambetti, M.
    Woodward, N.
    Ten Tije, A. J.
    Lindegger, N.
    Crespel, G.
    Truman, M.
    Steger, G. G.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S105 - S106
  • [32] Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients
    Shing, M.
    Jung, K. H.
    Ataseven, B.
    Verrill, M.
    De laurentiis, M.
    Azim, H. A.
    Pivot, X.
    Al-Sakaff, N.
    Lauer, S.
    Gligorov, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 19 - 20
  • [33] Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses
    Jung, K. H.
    Ataseven, B.
    Verrill, M.
    De laurentiis, M.
    Azim, H. A.
    Pivot, X.
    Al-Sakaff, N.
    Lauer, S.
    Shing, M.
    Gligorov, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S318 - S318
  • [34] Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability
    Jung, K. H.
    Ataseven, B.
    Verrill, M.
    Pivot, X.
    De Laurentiis, M.
    Al-Sakaff, N.
    Lauer, S.
    Shing, M.
    Gligorov, J.
    Azim, H. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Gianni, Luca
    Pienkowski, Tadeusz
    Im, Young-Hyuck
    Roman, Laslo
    Tseng, Ling-Ming
    Liu, Mei-Ching
    Lluch, Ana
    Staroslawska, Elzbieta
    de la Haba-Rodriguez, Juan
    Im, Seock-Ah
    Pedrini, Jose Luiz
    Poirier, Brigitte
    Morandi, Paolo
    Semiglazov, Vladimir
    Srimuninnimit, Vichien
    Bianchi, Giulia
    Szado, Tania
    Ratnayake, Jayantha
    Ross, Graham
    Valagussa, Pinuccia
    LANCET ONCOLOGY, 2012, 13 (01): : 25 - 32
  • [36] Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
    O'Shaughnessy, Joyce
    Sousa, Susana
    Cruz, Josefina
    Fallowfield, Lesley
    Auvinen, Paivi
    Pulido, Catarina
    Cvetanovic, Ana
    Wilks, Sharon
    Ribeiro, Leonor
    Burotto, Mauricio
    Klingbiel, Dirk
    Messeri, Dimitri
    Alexandrou, Ari
    Trask, Peter
    Fredriksson, Judy
    Machackova, Zuzana
    Stamatovic, Ljiljana
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 223 - 232
  • [37] Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
    Jackisch, C.
    Kim, S. -B.
    Semiglazov, V.
    Melichar, B.
    Pivot, X.
    Hillenbach, C.
    Stroyakovskiy, D.
    Lum, B. L.
    Elliott, R.
    Weber, H. A.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 320 - 325
  • [38] FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.
    Li, Qiao
    Cheng, Ying
    Tong, Zhongsheng
    Liu, Yunjiang
    Wang, Xian
    Yan, Min
    Chang, Jianhua
    Wang, Shusen
    Du, Caiwen
    Li, Liang
    Wu, Chunjiao
    Wang, Mingxia
    Wang, Zhuo
    Wu, Zhuli
    Jin, Yongli
    Zhang, Yongjiao
    Hui, Ai-Min
    Wang, Xingli
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Subcutaneous trastuzumab - recent evidence on efficacy and safety in HER2-positive breast cancer patients
    Pogoda, Katarzyna
    Niwinska, Anna
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (02): : 93 - 99
  • [40] SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU
    Otoya, Iris
    Valdivieso, Natalia
    Morante, Zaida
    Castaneda, Carlos
    Neciosup, Silvia
    Calderon, Monica
    Gomez, Henry
    CANCER RESEARCH, 2024, 84 (09)
12345